## Amendments to the Claims:

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A pseudopeptide of at least 6 amino acids comprising at least one unit chosen from the B units of general formulae (I) and/or (II):

-NH-C-CH<sub>2</sub>-CH<sub>2</sub>-N-C- -N-CH<sub>2</sub>-CH<sub>2</sub>-C-NH-C- 
$$R_3$$
 (II)

in which:

 $R_1$ ,  $R_2$  and  $R_3$  each independently of one another represent an amino acid side chain and may be identical or different, and

X represents an oxygen or sulfur atom,

wherein the N-terminal of said unit is attached to the C-terminal of an amino acid or of a unit of said general formulae (I) or (II) and/or the C-terminal of said unit is attached to the N-terminal of an amino acid or of a unit of said general formulae (I) or (II).

- 2. (Original) The pseudopeptide as claimed in claim 1 having a size of at least 9 amino acids.
- 3. (Previously Presented) The pseudopeptide as claimed in claim 1, characterized in that X represents an oxygen atom.
- 4. (Previously Presented) The pseudopeptide as claimed in claim 1, characterized in that  $R_2$  represents a hydrogen atom.
- 5. (Previously Presented) A method for synthesizing a pseudopeptide as claimed in claim 1, characterized in that a monoprotected diamine of general formula IIIa or IIIb

Application No. 09/889,178

in which:  $R_1$ ,  $R_1$  and  $R_3$  each independently of one another represent an amino acid side chain and may be identical or different, and GP represents a group for protecting the amine functional group, is coupled with an amine in the presence of a carbonylating agent.

- 6. (Original) The method as claimed in claim 5, characterized in that GP is a Boc, Fmoc, Cbz or Alloc group.
- 7. (Previously Presented) The method as claimed in claim 5, characterized in that the carbonylating agent is chosen from N, N'-carbonyldiimidazole and triphosgene.
- 8. (Previously Presented) A reagent for detecting a pathological condition associated with the presence of endogenous or exogenous proteins, characterized in that it comprises, as reactive substance, at least one pseudopeptide as claimed in claim 1.
- 9. (Original) The reagent as claimed in claim 8, characterized in that the pseudopeptide is labeled with a tracer or biotin.
- 10. (Previously Presented) The reagent as claimed in claim 8, characterized in that the size of the pseudopeptide is at least 12 amino acids.
- 11. (Previously Presented) A kit for detecting a pathological condition associated with the presence of endogenous or exogenous proteins, characterized in that a reagent according to claim 8, is attached to a solid support which is immunologically compatible with said reagent.

## 12,-13. (Canceled)

14. (Previously Presented) A method for detecting and/or assaying an antigen present in a sample by a competition technique in which said sample is brought into contact, simultaneously or in two stages, with a predetermined quantity of an antibody directed against

a portion of the antigen and a predetermined quantity of a reagent as claimed in claim 8, and the presence and/or the quantity of antigen present in said sample is determined.

(Previously Presented) A method for detecting and/or assaying an antibody 15. present in a sample by a competition technique in which said sample is brought into contact simultaneously with a predetermined quantity of an antigen at least a portion of which is recognized by said antibody and a predetermined quantity of a reagent as claimed in claim 8, and the presence and/or the quantity of antibody present in said sample is determined.

## 16.-17. (Canceled)

MAR-01-2006 14:25

(Previously Presented) A pharmaceutical composition comprising, as active 18. ingredient, at least one pseudopeptide as claimed in claim 1, and a pharmaceutically acceptable excipient.